F Prime Capital is a venture capital firm that invests in technology and financial services companies. The firm focuses on early-stage investments, partnering with entrepreneurs to build significant, sustainable businesses.

F Prime Capital

Medical Devices Venture is a holding company that develops a portfolio of investments in Med Tech start-ups. The aim is to combine the expertise of researchers in hospital and university settings with industrialization and commercialization capabilities.

Medical Devices Venture

Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

Today our funds are larger and more global, but our teams are still small and local. We stay true to our entrepreneurial roots. In the US and Europe, we are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, our sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together we bring a world of insight, domain expertise and relationships to support our entrepreneurs. Without the pressure of fundraising from outside investors, we focus all of our time finding and helping great entrepreneurs build important companies.

Wellframe

Kensho

Cytek Biosciences

Denali Therapeutics

Even Financial

Beam Therapeutics

Blueprint Medicines

Checkmate Pharmaceuticals

Iora Health

Farapulse

Ivenix

Sana Biotechnology

Coherus Biosciences

Acacia Pharma

Adagene

Adaptimmune

Apellis Pharmaceuticals

Artemis Health

Avidity Biosciences

Structure Therapeutics

Tempest Therapeutics

Toast

TradeBlock

Verve Therapeutics

ViewRay

Orchard Therapeutics

OZiva

PatientPing

Precision BioSciences

Prime Medicine

Recurly

REGENXBIO

F-Prime Capital

It was a full house yesterday at the Broad Institute of MIT and Harvard for the 2024 #Science2Startup symposium. Thank you to everyone who joined us for a day filled with insightful presentations, engaging panel discussions, and valuable networking opportunities centered around the future of the #biotech industry.
 
Boston's vibrant #lifesciences ecosystem makes it an unparalleled hub for innovation, and we are thrilled to continue our efforts to drive forward scientific breakthroughs and entrepreneurial ventures.

On the F-Prime Capital team, we'd specifically like to thank Jessica Alston and Stacie Weninger for participating as Advisors, Chong Xu for moderating, and Alexander Munoz, MD, Raj Basak, Davina Magargal, Allison (Gosman) Kanter and Emily Tynan for their work on the Steering Committee.
 
Stay tuned for details on next year's event!
 
Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank

Thank you to our 2024 #Science2Startup fireside chat speaker, David R. Liu, Ph.D., and moderator, Deborah Palestrant, Ph.D., M.B.A., for kicking off this year's event.

During their discussion, Liu spoke about his professional and academic journey, how he began working with #VentureCapital organizations, how he stays committed to science and patient care, and more.

"Problem selection, still very very important. Trust, give anybody who wants to work with you, the opportunity to work with you, if possible. But developing a network of people you trust is really important for translation. And ultimately, for this audience, where I noticed everything was a therapeutics company, keep patient interest upfront. That's such an important guiding star and you can virtually never go wrong if you just keep patient interest upfront, it will help everything. And you also, coincidentally, build the most value if you end up keeping patient interest upfront because all of this is not just a marathon, it's an ultramarathon, so not letting the short-term eccentricities of what an investor did or didn't do, how the value of your stock, if it's publicly traded, is changing or not; don't let that bother you. In the end, if you are actually helping people, if you keep patient interest upfront, you will generate enough value that everybody will be happy that way, and more importantly, in the end, I don't think you're going to care that much about how many digits are in your bank account, which is not even associated with physical money anymore, but I think people will remember you for the impact you had on the lives of patients who maybe didn't have a treatment otherwise."


Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank │ Broad Institute of MIT and Harvard
#biotech #pharma #startup

Congratulations to Jeff Walsh, Melissa Bonner, Ph.D., and Lisa McGrath and the rest of the Nvelop Therapeutics team on your formal launch to develop the next generation of genetic medicines. This launch represents a significant step forward for the development of future genetic medicines for a wide range of diseases thanks to their approach of enabling highly efficient and cell-specific deliveries to a broad range of therapeutic cargoes.

“The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s CEO. “With the combination of best-in-class technologies, scientific co-founders with a deep track record in cell and gene therapy, and a team that has pioneered the development of some of the first approved therapies in the field, Nvelop is uniquely positioned to unlock the promise of genetic medicines.”

Learn more: https://bit.ly/4cR7VcI 

Jessica Alston #GeneticMedicine #healthcare

The 2024 #Science2Startup symposium is this Wednesday! After exciting discussions and powerful networking, 8 researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub. 

Thank you to our event co-hosts Atlas Venture, 5AM Ventures, Osage University Partners (OUP), RA Capital Management, and MassBio. 

Make sure to follow along for updates!

Join us for Demo Day[s] 10 on Thursday, April 11, to hear venture investor David Jegen, Fintech Sandbox Co-Founder and Managing Partner of F-Prime Capital, discuss the digitization of private markets, an investment theme he finds particularly interesting right now. https://bit.ly/48mXOc2

Metric
Company Name	F Prime Capital	Medical Devices Venture
Symbol
MSH ID	COM:FPRIMECAPITAL	COM:MEDICALDEVICESVENTURE
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Healthcare & Health Services
Industry	Venture Capital	Medical Devices
Country	US	FR
Stage
Employee Count	83
Website	fprimecapital.com	medicaldevicesventure.com
LinkedIn	f-prime-capital-partners	medical-devices-venture
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	16.37K
Web Traffic Growth	-0.50
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FPRIMECAPITAL

F Prime Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue